FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) announced the release of the third batch of its investigational drug product CYWC628 and its shipment to Australia to support an ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was manufactured under current Good Manufacturing Practices (cGMP) and passed all required safety and quality tests, enabling its use in the trial.
According to FibroBiologics, the additional drug supply will help clinical sites continue the study, which evaluates safety, tolerability and efficacy of CYWC628 as a topical allogeneic fibroblast cell-based therapy for refractory DFUs. The randomized, multicenter trial compares standard of care plus low- or high-dose CYWC628 to standard of care alone over up to 12 weeks of treatment. The company reported encouraging progress to date and anticipates reporting statistically significant interim primary outcome data in the second half of 2026.
Positive
- Third CYWC628 batch released and shipped to Australia for Phase 1/2 DFU trial support
- cGMP manufacturing and quality testing completed, enabling CYWC628 clinical use
- Randomized multicenter Phase 1/2 trial comparing low/high-dose CYWC628 plus standard care vs standard care only
- Interim data readout on primary outcomes anticipated in second half of 2026
Negative
- None.
Market reaction after Phase 1/2 trial supply: FBLG +5.67% in the Aug 27 session
In the Aug 27 session, FBLG gained 5.67%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.2% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | Third-batch manufacturing | Positive | -3.3% | Third CYWC628 batch completed manufacturing ahead of safety and quality testing. |
| Jun 16 | Patient dosing advance | Positive | -9.3% | Patient dosing advanced while a third GMP run supported ongoing trial supply. |
| Jun 03 | First patients dosed | Positive | +1.9% | First patients dosed in randomized Phase 1/2 diabetic foot ulcer study. |
| May 04 | Drug product release | Positive | -5.5% | First cGMP batch released after safety and quality testing for clinical use. |
| Mar 31 | Product manufacturing completed | Positive | +0.8% | First CYWC628 batch manufactured under CGMP standards for planned first-in-human trials. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
FBLG's clinical-trial announcements produced three divergences and two alignments, with the tag-specific average move at -3.07%.
Key Terms
cgmp regulatory
allogeneic medical
fibroblast cell-based therapy medical
refractory medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
"Having this batch released and on its way to
For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.
About CYWC628
CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy for wound healing. Preclinical data suggest CYWC628 may significantly accelerate wound healing compared to currently available treatments.
FibroBiologics is conducting a prospective, multicenter, randomized clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 weeks of treatment using either standard of care plus a low or high-dose of CYWC628, or standard of care only.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the sufficiency of drug product to report six-week interim safety and primary efficacy data, plans for, and the anticipated timing of the initiation and completion of, FibroBiologics' clinical trials, plans for, and the timing of, release of clinical trial results, and expectations relating to such clinical trial results. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) the ability of FibroBiologics to successfully prosecute its patent applications; (e) FibroBiologics' ability to manufacture its product candidates; (f) FibroBiologics' ability to conduct clinical trials; and (g) the Company's ability to maintain compliance with applicable Nasdaq rules. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-releases-third-batch-of-cywc628-drug-product-for-phase-12-diabetic-foot-ulcer-clinical-trial-302861783.html
SOURCE FibroBiologics, Inc.